Lviv clinical bulletin 2015, 2(10)-3(11): 55-60

https://doi.org/10.25040/lkv2015.023.055

Heparins: Mechanism of Action and Application in Acute Pancreatitis

Posted onAuthorAdminЗалишити коментар / Leave a comment

S. Chooklin, B. Pidhirnyy, S. Chuklin

Lviv Regional Clinical Hospital

Introduction. Heparin is a glycosaminoglycan composed of chains of alternating d-glucosamine and uronic acid residues. Its major anticoagulant effect is attributed to a unique pentasaccharide structure. Heparin prevents coagulation after binding with a plasma antithrombin III. Antithrombin III is a protease inhibitor and complex heparin antithrombin III inhibits activity of thrombin, as well as neutralizes active forms of factors IX, X, XI and XII. However, the most important action of heparin is not inhibition of thrombin activity, but inhibition of thrombin creation, especially through accelerating the neutralization of factor Xa. In large concentration, heparin combined with antithrombin III also inhibits platelet aggregation.

Aim. To analyze the mechanism of action of heparin and its application for the treatment of patients with acute pancreatitis.

Materials and methods. Content analysis, method of system and comparative analysis, bibliosemantic method of study of actual scientific researches concerning the mechanism of action of heparin and its application for the treatment of patients with acute pancreatitis was used.

Results. In various experimental and clinical studies, heparin has been found to exhibit the anti-inflammatory activity. Heparin has shown protective and therapeutic effect in patients suffering from a range of inflammatory diseases, including rheumatoid arthritis, bronchial asthma, allergy and ulcerative colitis.

The heparin-antithrombin III complex significantly reduces the activity of trypsin and chymotrypsin.

There are experimental and some clinical studies showing protective and therapeutic effect of heparin in the pancreas. Experimental data indicate that pretreatment with heparin inhibits the development of acute pancreatitis evoked by bile, taurocholate, cerulein, or pancreatic ischemia followed by reperfusion. There are also experimental studies showing therapeutic effect of heparin in the course of acute pancreatitis. Clinical reports concern mainly the role of heparin in the prevention of acute pancreatitis due to endoscopic retrograde cholangiopancreatography and treatment of acute pancreatitis evoked by hyperlipidemia.

Conclusions. The administration of heparin enhances the effect of conventional treatment of severe acute pancreatitis, markedly decreases the incidence of encephalopathy and improves the survival rate in patients with this disease. Due to the anticoagulation and anti-inflammatory properties, accessibility, ease of use of low molecular weight heparins they can be included in the complex treatment of patients with severe pancreatitis, especially at an early stage of the disease, for the purpose of prevention and correction of organ dysfunction.

References

  1. Ahmed T, Garrigo J, Danta I. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med. 1993;329:90-95. https://doi.org/10.1056/NEJM199307083290204
  2. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731. https://doi.org/10.1155/2012/676731
  3. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem. 1982;48:161-182. https://doi.org/10.1007/BF00421226
  4. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis. 1993;147:160-163. https://doi.org/10.1164/ajrccm/147.1.160
  5. Buyue Y, Misenheimer TM, Sheehan JP. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism. J Thromb Haemost. 2012;10:2086-2098. https://doi.org/10.1111/j.1538-7836.2012.04892.x
  6. Yang L, Sun MF, Gailani D, Rezaie AR. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry. 2009;48:1517-1524. https://doi.org/10.1021/bi802298r
  7. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc. 2002;55(4):476-483. https://doi.org/10.1067/mge.2002.122616
  8. Axelsson J, Ferreira M, Adolfsson L, McCrea K, Ward R, Larm O. Cytokines in blood from septic patients interact with surface-immobilized heparin. ASAIO J. 2010;56(1):48-51. https://doi.org/10.1097/MAT.0b013e3181c3fec8
  9. Mitsuguro M, Okamoto A, Shironouchi Y, Sano M, Miyata S, Neki R et al. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol. 2015;101(2):119-125. https://doi.org/10.1007/s12185-014-1702-z
  10. Hackert T, Werner J, Gebhard MM, Klar E. Effects of heparin in experimental models of acute pancreatitis and post-ERCP pancreatitis. Surgery. 2004;135(2):131-138. https://doi.org/10.1016/j.surg.2003.08.001
  11. Du JD, Zheng X, Huang ZQ, Cai SW, Tan JW, Li ZL et al. Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis. Exp Ther Med. 2014;8(1):141-146. https://doi.org/10.3892/etm.2014.1694
  12. Lu XS, Qiu F, Li YX, Li JQ, Fan QQ, Zhou RG. Effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy in the patient with severe acute pancreatitis. Pancreas. 2010;39(4):516-519. https://doi.org/10.1097/MPA.0b013e3181c3c954
  13. Ke L, Ni HB, Tong ZH, Li WQ, Li N, Li JS. Efficacy of continuous regional arterial infusion with low-molecular-weight heparin for severe acute pancreatitis in a porcine model. Shock. 2014;41(5):443-448. https://doi.org/10.1097/SHK.0000000000000129
  14. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20(6):497-504. https://doi.org/10.1097/MOL.0b013e3283319a1d
  15. Fine NL, Shim C, Williams MH. Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis. 1968;98(5):886-887.
  16. Finotti P, Corvaja C, Pagetta A. Differential mechanisms for structural and functional alterations of trypsin by heparin, evidence for a specific, radical-generating mechanism at low heparin concentrations. Free Radic Biol Med. 1999;27(11-12):1378-1385. https://doi.org/10.1016/S0891-5849(99)00185-9
  17. Finotti P, Manente S. Heparin-induced structural and functional alterations of bovine trypsin. Biochem Biophys Acta. 1994;1207(1):80-87. https://doi.org/10.1016/0167-4838(94)90054-X
  18. Gaffney A, Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol. 1996;35(8):808-809. https://doi.org/10.1093/rheumatology/35.8.808
  19. García PS, Gulati A, Levy JH. The role of thrombin and protease-activated receptors in pain. Thromb Haemost. 2010;103(6):1145-1151. https://doi.org/10.1160/TH09-12-0848
  20. Gotte M. Syndecans in inflammation. FASEB J. 2003;17(6):575-591. https://doi.org/10.1096/fj.02-0739rev
  21. Ceranowicz P, Dembinski M, Warzecha Z et al. Healing effect of heparin in the course of edematous, cerulean-induced acute pancreatitis. Przeglad Gastroenterol. 2009;4:199-205.
  22. dela Paz NG, Melchior B, Shayo FY, Frangos JA. Heparіn sulfates mediate the interaction between platelet endothelial cell adhesion molecule-1 (PECAM-1) and the Gαq/11 subunits of heterotrimeric G proteins. J Biol Chem. 2014;289(11):7413-7424. https://doi.org/10.1074/jbc.M113.542514
  23. Alagozlu H, Cindoruk M, Karakan T, Unal S. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci. 2006;51(5):931-933. https://doi.org/10.1007/s10620-005-9006-z
  24. Dobosz M, Wajda Z, Hac S, Mysliwska J, Mionskowska L, Bryl E et al. Heparin and nitric oxide treatment in experimental acute pancreatitis in rats. Forum (Genova). 1998;8(3):303-310.
  25. Gabryelewicz A, Niewiarowski S, Prokopowicz J, Chlebowski J. Heparin and protease inhibitors in the prevention of experimental acute pancreatic necrosis in dogs. Digestion. 1969;2(1):7-16. https://doi.org/10.1159/000196915
  26. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Piqué JM et al. Heparin attenuates TNF alpha induced inflammatory response through a CD11b dependent mechanism. Gut. 2000;47(1):88-96. https://doi.org/10.1136/gut.47.1.88
  27. Ranjbaran H, Wang Y, Manes TD, Yakimov AO, Akhtar S, Kluger MS et al. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation. 2006;114(12):1293-1300. https://doi.org/10.1161/CIRCULATIONAHA.106.631457
  28. Arimateia DS, da Silva Brito A, de Azevedo FM, de Andrade GP, Chavante SF. Heparin fails to inhibit the leukocyte recruitment for an extended time following inflammatory stimulus. Pharm Biol. 2015;53(1):72-77. https://doi.org/10.3109/13880209.2014.910534
  29. Dobosz M, Mionskowska L, Hac S, Dobrowolski S, Dymecki D, Wajda Z. Heparin improves organ microcirculatory disturbances in caerulein-induced acute pancreatitis in rats. World J Gastroenterol. 2004;10(17):2553-2256. https://doi.org/10.3748/wjg.v10.i17.2553
  30. Warzecha Z, Dembinski A, Ceranowicz P, Dembinski M, Sendur R, Cieszkowski J et al. Heparin inhibits protective effect of ischemic preconditioning in ischemia/reperfusion-induced acute pancreatitis. J Physiol Pharmacol. 2012;63(4):355-365.
  31. Li L, Ling Y, Huang M, Yin T, Gou SM, Zhan NY et al. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine. 2015;72(1):36-42. https://doi.org/10.1016/j.cyto.2014.12.010
  32. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: Potential therapeutic applications beyond. Adv Pharmacol. 1999;46:151-208. https://doi.org/10.1016/S1054-3589(08)60471-8
  33. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol. 1995;130(6):1473-1482. https://doi.org/10.1083/jcb.130.6.1473
  34. Wang L, Brown JR, Varki A, Esko JD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002;110(1):127-136. https://doi.org/10.1172/JCI0214996
  35. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP et al. Heparins increase endothelial nitric oxide bioavailability by liberating vesselimmobilized myeloperoxidase. Circulation. 2006;113(15):1871-1878.https://doi.org/10.1161/CIRCULATIONAHA.105.590083
  36. Warzecha Z, Dembiński M, Ceranowicz P, Dembiński A. Heparyna i jej działanie przeciwzapalne w układzie pokarmowym. Gastroenterologia Polska. 2010;17(3):227-233.
  37. Rosenberg RD, Jordan RE, Favreau LV, Lam LH. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 1979;86(4):1319-1324. https://doi.org/10.1016/0006-291X(79)90260-2
  38. Monga A, Arora A, Makkar RP, Gupta AK. Hypertriglyceridemia-induced acute pancreatitis – treatment with heparin and insulin. Indian J Gastroenterol. 2003;22(3):102-103.
  39. Evangelista V, Piccardoni P, Maugeri N, De Gaetano G, Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol. 1992;216(3):401-405. https://doi.org/10.1016/0014-2999(92)90437-9
  40. Jain P, Rai RR, Udawat H, Nijhawan S, Mathur A. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol. 2007;13(18):2642-2643. https://doi.org/10.3748/wjg.v13.i18.2642
  41. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement – their role in inflammation. Semin Immunopathol. 2012;34(1):151-165. https://doi.org/10.1007/s00281-011-0280-x
  42. Lee MJ. Heparin inhibits activation of latent transforming growth factor-β1. Pharmacology. 2013;92(5-6):238-244. https://doi.org/10.1159/000355837
  43. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol. 2010;299(1):C97-C110. https://doi.org/10.1152/ajpcell.00009.2010
  44. Barkay O, Niv E, Santo E, Bruck R, Hallak A, Konikoff FM. Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc. 2008;22(9):1971-1976. https://doi.org/10.1007/s00464-007-9738-2
  45. Li S, Cao G, Chen X, Wu T. Low-dose heparin in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2012;24(5):477-481. https://doi.org/10.1097/MEG.0b013e328351097f
  46. Lu XS, Qiu F, Li JQ, Fan QQ, Zhou RG, Ai YH et al. Low molecular weight heparin in the treatment of severe acute pancreatitis: a multiple centre prospective clinical study. Asian J Surg. 2009;32(2):89-94. https://doi.org/10.1016/S1015-9584(09)60017-8
  47. Ning F, Wang X, Shang L, Wang T, Lv C, Qi Z et al. Low molecular weight heparin may prevent acute lung injury induced by sepsis in rats. Gene. 2015;557(1):88-91. https://doi.org/10.1016/j.gene.2014.12.018
  48. Wang XF, Li AM, Li J, Lin SY, Chen CD, Zhou YL et al. Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1β and inhibiting syndecan-1 shedding in the intestinal mucosa. PLoS One. 2013;8(7):e66397. https://doi.org/10.1371/journal.pone.0066397
  49. Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem. 2006;6(9):1009-1023. https://doi.org/10.2174/138955706778195180
  50. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Disc Technol. 2009;6(4):281-289. https://doi.org/10.2174/157016309789869001
  51. Kyriakidis AV, Raitsiou B, Sakagianni A, Harisopoulou V, Pyrgioti M, Panagopoulou A et al. Management of acute severe hyperlipidemic pancreatitis. Digestion. 2006;73(4):259-264. https://doi.org/10.1159/000095425
  52. Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science. 1989;245(4923):1238-1241. https://doi.org/10.1126/science.2551036
  53. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernandez C, Vargas-Castrillon E. New parenteral anticoagulants in development. Therap Adv Cardiovasc. Dis. 2011;5(1):33-59. https://doi.org/10.1177/1753944710387808
  54. Shastri MD, Peterson GM, Stewart N, Sohal SS, Patel RP. Non-anticoagulant derivatives of heparin for the management of asthma: distant dream or close reality? Expert Opin Investiq Drugs. 2014;23(3):357-373. https://doi.org/10.1517/13543784.2014.866092
  55. Perretti M, Page CP. Heparin and inflammation: a new use for an old GAG? Gut. 2000;47(1):14-15. https://doi.org/10.1136/gut.47.1.14
  56. Köksoy FN, Yankol Y, Şen Oran E, Őzkan Gūrdal S, Yūksel M, Akyildiz Iğdem A et al. Preventive effects of enoxaparin and hesperidin in cerulein-induced acute pancreatitis in rats. Turk J Gastroenterol. 2013;24(6):495-501. https://doi.org/10.4318/tjg.2013.0585
  57. Ceranowicz P, Dembinski A, Warzecha Z, Dembinski M, Cieszkowski J, Rembisz K et al. Protective and therapeutic effect of heparin in acute pancreatitis. J Physiol Pharmacol. 2008;59(4 Suppl):103-125.
  58. Wan MX, Liu Q, Wang Y, Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: role of neutrophil recruitment and TNF-alpha production. Inflamm Res. 2002;51(4):182-187. https://doi.org/10.1007/PL00000290
  59. Qiu F, Lü XS, Huang YK. Effect of low molecular weight heparin on pancreatic micro-circulation in severe acute pancreatitis in a rodent model. Chin Med J. 2007;120(24):2260-2263.
  60. Li S, Chen X, Wu T, Zhang M, Zhang X, Ji Z. Role of heparin on serum VEGF levels and local VEGF contents in reducing the severity of experimental severe acute pancreatitis in rats. Scand J Gastroenterol. 2012;47(2):237-244. https://doi.org/10.3109/00365521.2011.647063
  61. Saito A. Heparin cofactor II is degraded by heparan sulfate and dextran sulfate. Biochem Biophys Res Commun. 2015;457(4):585-588. https://doi.org/10.1016/j.bbrc.2015.01.028
  62. Lever R, Lo WT, Faraidoun M, Amin V, Brown RA, Gallagher J et al. Size-fractionated heparins have differential effects on human neutrophil function in vitro. Br J Pharmacol. 2007;151(6):837-843. https://doi.org/10.1038/sj.bjp.0707298
  63. Spyropoulos AC. Current and emerging anticoagulation therapies for the management of venous thromboembolism in nonsurgical patients. Thrombosis Clinic. 2008;2:31-46.
  64. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. ‘Sticky’ neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut. 1995;37(4):585-588. https://doi.org/10.1136/gut.37.4.585
  65. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest. 1989;83(3):752-756. https://doi.org/10.1172/JCI113953
  66. Petitou M, Duchaussoy P, Jaurand G, Gourvenec F, Lederman I, Strassel JM et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem. 1997;40(11):1600-1607. https://doi.org/10.1021/jm960726z
  67. Chang CH, Lico LS, Huang TY, Lin SY, Chang CL, Arco SD et al. Synthesis of the heparin-based anticoagulant drug fondaparinux. Angew Chem Int Ed Engl. 2014;53(37):9876-9879. https://doi.org/10.1002/anie.201404154
  68. Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis. Crit Care Med. 2015;43(3):511-518. https://doi.org/10.1097/CCM.0000000000000763
  69. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):495-530.
  70. Li X, Li Z, Zheng Z, Liu Y, Ma X. Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-ĸB signaling pathway. Inflammation. 2013;36(6):1201-1208. https://doi.org/10.1007/s10753-013-9656-5